ASBP is trading at $5.51, down 5.97% in after-hours trading, as the stock gives back a portion of its 9.74% regular-session gain amid broader market softness.
- The move appears to be driven by profit-taking following a volatile stretch, as no new company-specific announcements were released after the market close.
- Broader market pressure is likely weighing on small-cap biotech names, with the NASDAQ Composite down 0.97%.
- While recent coverage has focused on FDA pre-IND optimism, no fresh catalysts have emerged to explain the late-session decline.